GW25-e4428 Exogenous Hydrogen Sulfide Delays Nicotinamide-Induced Premature Senescence via SIRT1 pathway in Human Umbilical Vein Endothelial Cells  by Weili, Qiao et al.
Results: The recombinant lentivirus plasmid carrying ZO-1 was correctly constructed,
it was identiﬁed correct by double enzyme digestion and DNA sequencing. The
lentiviral packaging was succeed, and the titer of lentivirus was 1.42108IU/ml.
Conclusion: Lenti-EF1a-EGFP-TRE-ZO1 lentiviral vector has been successfully
constructed. The titer of lentivirus was 1.42108IU/ml, it was used to infect iPS cells,
which will be useful for further study in vivo, to understand its function and its unique
effects under different pathological status of heart, and open new doors for the
treatment of cardiovascular diseases.
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Objectives: The present study was designed to observe the effect of hydrogen sulﬁde
(H2S) on cellular senescence of human umbilical vascular endothelial cells (HUVECs
CC-2517) and its underlying mechanism.
Methods: The premature senescence-like phenotypeHUVECs (the fourth passage) was
induced by nicotinamide (NAM, an inhibitor of SIRT1) at the concentration of 5mmol/L
for 12 hours. Cells were cultured with sodium hydrosulﬁde (NaHS, 12.5, 25, 50,
100mmol/L) added into the fresh medium for 48 hours on the basis of premature
senescence-like phenotyoe HUVECs. The fourth passage of HUVECs was considered
as young group. Senescence associated (SA) -b-galactosidase activities were detected to
evaluate cell senescence, and the expression of senescence associated heterochromatin
foci (SAHF) was visualized by DAPI DNA staining. The mRNA and protein levels of
SIRT1 were detected using RT-PCR and western blotting analysis, respectively.
Results: The results showed that b-galactosidase positive cells and the formation of
SAHF were markedly increased after treatment with NAM (5mmol/L) for 12h. We also
found that NaHS (12.5mmol/L) had no effect on the percentage of SA b-gal positive cells
and the expression of SAHF, and the hallmarks decreased at the concentration of 25 and
50mmol/L, reaching the minimum at 50 mmol/L, while the percentage of SA b-gal
positive cells and the expression of SAHF increased at the concentration of 100mmol/L.
Furthermore we found that SIRT1 expression both on protein and mRNA in the
Y+N+S50 group was signiﬁcantly increased compared with that in Y+N group.
Conclusions: NaHS delays senescence of HUVECs induced by NAM via up-regu-
lation of SIRT1 expression.
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Objectives: Cardiac channelopathies are primary arrhythmias caused by variations in
the genes encoding cardiac ion channels. It is one of the major causes which could
lead to sudden cardiac death.
Methods: The pathological change leading to cardiac channelopathies is intimately
linked to the geno-variations. MicroRNAs (miRNAs) are one of the participants that
regulate the target gene expression.
Results: Burgeoning evidences indicated that miRNAs are closely associated with
myocardial development, proliferation, differentiation, apoptosis and ion channel
remodeling, especially involved in arrhythmias, congenital heart disease, hyperten-
sion, and myocardial ischemia. In vivo and in vitro studies suggested that miRNAs
may serve as a diagnostic biomarker for cardiac channelopathies. They can modulate
the function of cardiac ion channel genes and would be a good choice to act as a
miRNA-based therapy method.
Conclusions:We review the mechanisms and functions of miRNAs related to cardiac
ion channels and focus on the potential perspective of miRNAs as a novel therapeutic
target for cardiac channelopathies.
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Objectives: This study was designed to evaluate the impact of a glucagon-GLP-1
dual-agonist (ZP2495) on cardiac function and energy metabolism after myocardial
ischemia-reperfusion injury in db/db mice, and the underlying mechanisms involved.
Methods: The peptides of glucagon, GLP-1 receptor agonist (ZP131) and glucagon-
GLP-1 dual-agonist (ZP2495) were synthesized and puriﬁed by ChinaPeptides. Wild-
type (WT) and db/db mice received 4-weeks treatment of glucagon, ZP131 or ZP2495
followed by left anterior descending coronary artery (LAD) ligation and reperfusion.
Cardiac function, hemodynamic parameters, glucose metabolism, myocardial infarct
size, cardiomyocyte apoptosis, mitochondrial ultrastructural morphology, mitochon-
drial respiration and ATP synthesis were measured. Mitochondrial membraneC44 JACC Vol 64/16/Suppl C j Octobpotential, mitochondrial cytochrome c release and mitochondria reactive oxygen
species (ROS) generation were assessed in high-glucose-induced neonatal rat ven-
tricular myocytes (NRVMs) after simulated ischemia/reperfusion (SI/R) injury. The
expressions of FoxO3a, phospho-FoxO3a (Thr32, Ser413), Akt, phospho-Akt
(Ser473, Thr308) AMPK, phospho-AMPK (Thr172), Bim, Bax, Bcl-2, Bad, phospho-
Bad, MnSOD, Catalase,Sirt1, PGC1a, Acetylated-Lysine, Nrf-1, Tfam of the heart
tissue were detected by Western blot.
Results: ZP2495 treatment improved cardiac function and cardiac glucose metabolism,
decreased apoptotic cardiomyocytes, improvedmitochondrial ultrastructural morphology
and mitochondrial energetic transition of db/db mice after cardiac I/R injury. ZP2495
treatment preventedmitochondrial depolarization and reduced the release of cytochrome c
and mitochondria reactive oxygen species (ROS) generation in high-glucose-induced
NRVMs after SI/R injury. Western blot revealed that ZP2495 exerted anti-apoptotic
and anti-oxidation effect on cardiomyocyte of db/db mice after cardiac I/R injury via
Akt/FoxO3a-dependent mechanism. In addition, ZP2495 improved energy metabolism
and increased mitochondrial biogenesis in hearts of db/db mice subjected to I/R injury
through AMPK/FoxO3a and AMPK-SIRT1-PGC-1a pathway.
Conclusions: Glucagon and GLP-1 dual-agonist (ZP2495) protects against myocar-
dial I/R injury in db/db mice, which may contribute to the improvement of cardiac
function and cardiac energy metabolism. The protective effects of ZP2495 may be
associated with the Akt/FoxO3a, AMPK/FoxO3a and AMPK-SIRT1-PGC-1a path-
ways activation.
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Objectives: Autophagy is activated in hypertension-induced cardiac hypertrophy, in
which the mechanisms are not clear. Our previous study has demonstrated that ator-
vastatin inhibites heart remodeling spontaneously hypertensive rats (SHR). This study
was designed to determine the regulation of atorvastatin on cardiac autophagy in
SHRs.
Methods: Twenty-four male SHRs at 8 weeks of age were randomly divided into four
groups receiving vehicle (SHR+V) or atorstatin at a dose of 50 mg/kg/day
(SHR+ATO) until ages of 6 months or 12 months old. WKY rats were used as
controls. Cardiac magnetic resonance (CMR) was used to evaluate heart functions.
Autophagy was demonstrated by the up-regulated expression of microtubule-associ-
ated protein-1 light chain 3-II (LC3-II), Beclin-1, caspase-3, the formation of auto-
phagosomes, and by the electron microscopic ﬁndings. Western blot analysis shows
the expression of the proteins.
Results: Atorstatin treatments for both 4 and 10 months signiﬁcantly attenuated car-
diac dysfunction, remodeling, and atrial natriuretic peptide expression in SHRs, which
were increased compared with WKY rats. At 12 months of age, autophagy was found
to be activated in the heart of SHRs treated with vehicle or atorstatin. The activated
autophagy was especially increased in the cardiomyocytes of SHRs with atorstatin
treatment for 10 months. P-Akt and P-mTor decreased in the heart of SHR versusWKY
rats, while atorstatin further decreased cardiac akt and mTor phosphorylation.
Conclusions: These ﬁndings suggest that atorvastatin attenuated cardiac remodeling
and heart dysfunction in SHR probably through its regulation on cardiac autophagy
via akt/mTor pathways.
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Objectives: Cell-released microvesicles (MVs) are implicated in mediating cell-to-cell
communication and are able to modulate target cell functions. Previous evidence in-
dicates that endothelial progenitor cells (EPCs) -derived MVs can modulate endo-
thelial cell survival and proliferation. In this study, we evaluated whether EPC-MVs
could protect cardiomyocytes (CMs) against angiotensin II (Ang II) -induced hyper-
trophy and apoptosis.
Methods: The cell line H9c2 CMs were exposed to Ang II in the presence or absence
of EPC-MVs. Cell viability, apoptosis, surface area and b-myosin heavy chain
(b-MHC) expression were analyzed. To investigate the underlying mechanisms,
reactive oxygen species (ROS) generation, serine/threonine kinase (Akt), phospho-Akt
(P-Akt), endothelial nitric oxide synthase (eNOS) and phospho-eNOS (P-eNOS)
expression levels were measured. The inhibitors of phosphatidylinositol-3-kinase
(PI3K) and NOS were used for pathway veriﬁcation. The role of MV carried RNAs in
mediating these effects was also explored.
Results: Results showed: (1) EPC-MVs were able to protect CM against Ang II-in-
duced changes in cell viability, apoptosis, surface area and b-MHC expression;er 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
